The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
News|Articles|June 9, 2026
FDA Flashback: Breast Cancer Decisions and News From May 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.
Advertisement
Advertisement
Catch a glimpse of the breast cancer–related FDA decisions granted in May 2026, including several drug approvals and an updated Prescription Drug User Fee Act (PDUFA) target action date.
Related to this article
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
SOT106 now holds both orphan drug and fast track designations across soft tissue sarcoma and osteosarcoma ahead of a first-in-human trial.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
Advertisement
Advertisement